The effect of aspirin in patients with nonvaricose upper gastrointestinal bleeding and risk factors analysis

Abstract

Objective

This paper aims to explore the effect of aspirin on the in-hospital mortality of patients with NVUGIB.

Methods

An observational study retrospectively examined 1514 patients with NVUGIB based on a multi-center database.

Result

Our study reported a mortality rate of 4.8% in patients with NVUGIB, with 163 patients had a history of aspirin. Among 163 patients with an aspirin history, 76 patients (46.6%) continued to take aspirin in the hospital, with an average duration of 0.66 days after bleeding. Subsequent multivariate regression analysis showed heart rate (p <.001, OR = 0.978, 95%CI 0.969–0.987) and albumin (p =.019, OR = 0.658, 95%CI 0.464–0.933) were independent factors for aspirin-therapy after bleeding. Patients who received aspirin after NVUGIB (log-rank = 3.968, p =.046) had better survival than those who did not, but it was not an independent risk factor. The levels of albumin (p < .001, OR = 0.288, 95%CI 0.165–0.505) and INR (p =.013, OR = 1.166, 95%CI 1.033–1.316) and heart rate (p =.005, OR = 1.017, 95%CI 1.005–1.029) were independent factors of in-hospital mortality.

Conclusions

The independent risk factors for in-hospital mortality in patients with NVUGIB were albumin and INR and heart rate. The history of aspirin and the aspirin therapy after the bleeding did not affect the in-hospital mortality in patients with NVUGIB.

Keywords:

• Aspirin
• NVUGIB
• in-hospital mortality

Acknowledgments

The authors thank the Philips eICU Research Institute and Philips Healthcare for their contribution to the data. The authors also thank Andrew A. Kramer for insightful comments regarding the data and Dina Demner-Fushman for helpful feedback on the deidentification process.

Disclosure statement

No potential conflict of interest was reported by the author(s).